Anti-APOB/ FLDB/ LDLCQ4 monoclonal antibody
Anti-APOB/ FLDB/ LDLCQ4 antibody for FACS & in-vivo assay
Go to APOB/APOB products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T07533-Ab-1/ GM-Tg-hg-T07533-Ab-2 | Anti-Human APOB monoclonal antibody | Human |
GM-Tg-rg-T07533-Ab-1/ GM-Tg-rg-T07533-Ab-2 | Anti-Rat APOB monoclonal antibody | Rat |
GM-Tg-mg-T07533-Ab-1/ GM-Tg-mg-T07533-Ab-2 | Anti-Mouse APOB monoclonal antibody | Mouse |
GM-Tg-cynog-T07533-Ab-1/ GM-Tg-cynog-T07533-Ab-2 | Anti-Cynomolgus/ Rhesus macaque APOB monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T07533-Ab-1/ GM-Tg-felg-T07533-Ab-2 | Anti-Feline APOB monoclonal antibody | Feline |
GM-Tg-cang-T07533-Ab-1/ GM-Tg-cang-T07533-Ab-2 | Anti-Canine APOB monoclonal antibody | Canine |
GM-Tg-bovg-T07533-Ab-1/ GM-Tg-bovg-T07533-Ab-2 | Anti-Bovine APOB monoclonal antibody | Bovine |
GM-Tg-equg-T07533-Ab-1/ GM-Tg-equg-T07533-Ab-2 | Anti-Equine APOB monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T07533-Ab-1/ GM-Tg-hg-T07533-Ab-2; GM-Tg-rg-T07533-Ab-1/ GM-Tg-rg-T07533-Ab-2; GM-Tg-mg-T07533-Ab-1/ GM-Tg-mg-T07533-Ab-2; GM-Tg-cynog-T07533-Ab-1/ GM-Tg-cynog-T07533-Ab-2; GM-Tg-felg-T07533-Ab-1/ GM-Tg-felg-T07533-Ab-2; GM-Tg-cang-T07533-Ab-1/ GM-Tg-cang-T07533-Ab-2; GM-Tg-bovg-T07533-Ab-1/ GM-Tg-bovg-T07533-Ab-2; GM-Tg-equg-T07533-Ab-1/ GM-Tg-equg-T07533-Ab-2 |
Products Name | Anti-APOB monoclonal antibody |
Format | mab |
Target Name | APOB |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-APOB benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species APOB/ FLDB/ LDLCQ4 VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-T07533 |
Target Name | APOB |
Gene ID | 338,238055,54225,702937,475680,101098863,494004,100071824 |
Gene Symbol and Synonyms | Aa1064,Ac1-060,Apo B-100,APOB,ApoB(100),apoB-100,apoB-48,FCHL2,FLDB,LDLCQ4 |
Uniprot Accession | P04114,Q7™A5 |
Uniprot Entry Name | APOB_HUMAN,APOB_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | Ovary Cancer |
Gene Ensembl | ENSG00000084674 |
Target Classification | N/A |
The target: APOB, gene name: APOB, also named as FLDB, LDLCQ4, apoB-100, apoB-48. This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins (LDL), and is the ligand for the LDL receptor. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq, Dec 2019].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.